Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Onto Innovation (ONTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Onto Innovation — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B), while Onto Innovation trades at $235.42 (market cap $11.85B). The key difference: Onto Innovation is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Onto Innovation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Onto Innovation for 7 Days on average.
| HNGE | ONTO | |
|---|---|---|
Market Cap | $8.47B | $11.85B |
Volume | 1,624,526 | 1,876,863 |
Sector | Health | Technology |
52-Week High | $105.14 | $378.45 |
52-Week Low | $31.17 | $124.09 |
Typical Hold Time | 0 Days | 7 Days |
Enterprise Value | $8.09B | $11.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
ONTO trades at $263.55, down 3.72% with bearish technical signals but strong analyst support. The stock shows mixed earnings performance with a Q2 2026 beat but misses in prior quarters. Revenue grew to $1.01B in 2025 with 11.84% net margin, though valuation remains elevated at P/E 98.71. Recent news highlights a $1.1B backlog and strategic partnerships in semiconductor manufacturing.
Outlook remains positive with 100% analyst buy ratings and $387 consensus target suggesting 47% upside. Key risks include high valuation multiples and semiconductor cycle volatility. Growth catalysts include AI-driven demand and Dragonfly G5 product momentum, though execution on backlog conversion is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Onto Innovation
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →
